Targeting sFRP1 with WAY-316606 Suppresses Proliferation, Migration, and Invasion in Metastatic Melanoma
Cancers · 25.05.2026 · 18 (11) · 1721
DOI: 10.3390/cancers18111721 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 25.05.2026. Verfasst von Dokyeong Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Background/Objectives: Melanoma is a highly aggressive cancer with a strong metastatic potential, and therapeutic resistance remains a major clinical challenge despite advances in targeted therapies and immunotherapies. Secreted frizzled-related protein 1 (sFRP1) exhibits context-dependent roles in cancer; however, its function in metastatic melanoma remains poorly defined. This study investigated the role of sFRP1 in melanoma progression and evaluated the anti-tumor effects of the pharmacological compound WAY-316606. Methods: sFRP1 expression was quantified in metastatic melanoma cell lines, xenograft models, and TCGA datasets. The anti-tumor effects of WAY-316606 on cell viability, cell cycle progression, cell migration and invasion, and expression of extracellular matrix (ECM)-related genes were assessed using WST assays, flow cytometry, wound healing and transwell invasion assays, and quantitative real-time PCR, respectively. Results: sFRP1 expression was consistently elevated in metastatic melanoma cell lines, xenograft models, and TCGA datasets, and high sFRP1 expression was associated with poor overall survival. WAY-316606 selectively suppressed melanoma cell viability with minimal cytotoxic effects on non-tumorigenic cells, and induced G1 phase cell cycle arrest. Furthermore, WAY-316606 markedly impaired the migratory and invasive capacities of metastatic melanoma cells, accompanied by downregulation of key ECM remodeling and fibrosis-related genes, including VIM, CCN2, FN1, and TGFBI. sFRP1 knockdown partially phenocopied the anti-migratory and gene expression effects of WAY-316606. Conclusions: Collectively, our findings identify sFRP1-asscoaited signaling contribute to aggressive melanoma phenotypes and highlight the therapeutic potential of its pharmacological inhibition using WAY-316606.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Precision Medicine Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
- Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
- Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
- The Medical Basic Research Innovation Center of Airway Disease in North China, Jilin University, Changchun 130021, China.
- Department of Medical Sciences, Graduate School of The Catholic University of Korea, Seoul 06591, Republic of Korea.
ORCID-Profile: Dokyeong Kim, Junseong Park, Yeun-Jun Chung
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, D., Park, J., Na, O., Nam, D., Cho, S., Park, M., Zhang, S., & Chung, Y. J. (2026). Targeting sFRP1 with WAY-316606 Suppresses Proliferation, Migration, and Invasion in Metastatic Melanoma. Cancers, 18(11), 1721. https://doi.org/10.3390/cancers18111721
Vancouver
Kim D, Park J, Na O, Nam D, Cho S, Park M, et al. Targeting sFRP1 with WAY-316606 Suppresses Proliferation, Migration, and Invasion in Metastatic Melanoma. Cancers. 2026;18(11):1721. doi:10.3390/cancers18111721
BibTeX
@article{Kim2026,
author = {Kim, Dokyeong and Park, Junseong and Na, Okcho and Nam, Dahye and Cho, Sumin and Park, Minyoung and Zhang, Songzi and Chung, Yeun-Jun},
title = {Targeting sFRP1 with WAY-316606 Suppresses Proliferation, Migration, and Invasion in Metastatic Melanoma},
journal = {Cancers},
year = {2026},
volume = {18},
number = {11},
pages = {1721},
doi = {10.3390/cancers18111721}
}
EUVIMED